Shots:

• The first co-administration descriptive study evaluates Fluzone high-dose quadrivalent vaccine + Moderna’s COVID-19 mRNA booster dose (100 mcg dose) in 300 patients aged ≥65yrs. who received two doses of a COVID-19 mRNA vaccine as primary vaccination 5mos. prior to enrolment
• The results showed that both vaccines had similar immunogenicity responses along with similar safety and tolerability profile compared to each vaccine administered individually. The results will be published in 2021
• Fluzone high-dose quadrivalent is also licensed under the brand name Efluelda in the EU for adults aged ≥60yrs. Moderna’s application for a booster indication is currently under the US FDA’s review

  | Ref: Sanofi | Image: Evaluate Pharma